Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

NCT01218789 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Non 24 Hour Sleep Wake Disorder

Interventions

DRUG: tasimelteon

Sponsor

Vanda Pharmaceuticals